Longeveron's Lomecel-B™ improved cognitive function and brain volume in mild Alzheimer's patients in a Phase 2a trial.
Longeveron Inc., a regenerative medicine biotech firm, presented positive Phase 2a trial results for Lomecel-B™ at the Alzheimer's Association International Conference. The CLEAR MIND study showed Lomecel-B™ improved cognitive function, quality of life, and brain volume in 48 patients with mild Alzheimer's. The therapy met safety, target engagement, and efficacy objectives, with no serious adverse reactions.
July 28, 2024
3 Articles